CSL partners with Alentis Therapeutics to co-develop lixudebart, while Jiangsu Nhwa licenses a clinical-stage sleep disorder candidate to Somnivera.
Feature|Articles|June 9, 2026
Deepening Ties: Why China is Becoming Big Pharma's Most Essential R&D Partner
Author(s)Nicholas Jacobus
With more than $43 billion committed in five months, the pharma industry isn't just licensing from China, it's restructuring where global drug discovery begins.
Advertisement
Advertisement
The pace and scale of the pharma industry’s turn toward China in early 2026 is difficult to overstate, with more than $43 billion in licensing commitments in just five months. What is currently unfolding can be described as a structural realignment of where the global drug industry sources its innovation, and its terms.
Related to this article
Novo licensed Hengrui's once-weekly oral GLP-1/GIP dual agonist HRS-1596 in a deal worth up to $2.6 billion, while AstraZeneca invested $2 billion in Summit Therapeutics to pair ivonescimab with its antibody-drug conjugate portfolio.
Novartis licenses Abogen's mRNA-encoded CD19xCD3 T-cell engager, while AstraZeneca and Daiichi Sankyo partner with Summit Therapeutics.
New U.S. guidance exempts orphan drugs, nuclear medicines, cell and gene therapies, and other specialty products from the 100% pharmaceutical tariff when imported from 19 named countries.
Merck has acquired exclusive global rights to SciBrunch's preclinical KRAS G12D inhibitor SPR2015.
CORXEL’s chief medical value discusses how GLP-1s are becoming a chronic disease platform.
As Japan prices take on greater global significance, disciplined launch strategy can help pharma companies capture the full value of innovation.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
Advertisement
Advertisement